JP2025016538A5 - - Google Patents

Download PDF

Info

Publication number
JP2025016538A5
JP2025016538A5 JP2024185456A JP2024185456A JP2025016538A5 JP 2025016538 A5 JP2025016538 A5 JP 2025016538A5 JP 2024185456 A JP2024185456 A JP 2024185456A JP 2024185456 A JP2024185456 A JP 2024185456A JP 2025016538 A5 JP2025016538 A5 JP 2025016538A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024185456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025016538A (ja
Filing date
Publication date
Priority claimed from CN202011325843.0A external-priority patent/CN114524878B/zh
Application filed filed Critical
Publication of JP2025016538A publication Critical patent/JP2025016538A/ja
Publication of JP2025016538A5 publication Critical patent/JP2025016538A5/ja
Pending legal-status Critical Current

Links

JP2024185456A 2020-11-23 2024-10-21 二重特異性抗体及びその使用 Pending JP2025016538A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202011325843.0 2020-11-23
CN202011325843.0A CN114524878B (zh) 2020-11-23 2020-11-23 一种双特异性抗体及其用途
JP2023530940A JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用
PCT/CN2021/132195 WO2022105924A1 (zh) 2020-11-23 2021-11-22 一种双特异性抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023530940A Division JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2025016538A JP2025016538A (ja) 2025-02-04
JP2025016538A5 true JP2025016538A5 (https=) 2025-06-05

Family

ID=81618526

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023530940A Active JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用
JP2024185455A Pending JP2025016537A (ja) 2020-11-23 2024-10-21 二重特異性抗体及びその使用
JP2024185456A Pending JP2025016538A (ja) 2020-11-23 2024-10-21 二重特異性抗体及びその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2023530940A Active JP7846110B2 (ja) 2020-11-23 2021-11-22 二重特異性抗体及びその使用
JP2024185455A Pending JP2025016537A (ja) 2020-11-23 2024-10-21 二重特異性抗体及びその使用

Country Status (8)

Country Link
US (2) US20240002540A1 (https=)
EP (3) EP4691565A3 (https=)
JP (3) JP7846110B2 (https=)
KR (2) KR20230117160A (https=)
CN (4) CN114524878B (https=)
AU (2) AU2021383901B2 (https=)
CA (1) CA3199721A1 (https=)
WO (1) WO2022105924A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种t细胞衔接器治疗剂的开发和应用
CN114573702A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种新型肿瘤衔接器治疗药物的开发和应用
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
CN120712345A (zh) * 2022-12-30 2025-09-26 上药生物治疗(香港)有限公司 表达趋化因子受体的细胞及其用途
CN120513093A (zh) * 2023-03-18 2025-08-19 思道医药科技(苏州)有限公司 抗her3/muc1抗体及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス, インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
JP4658125B2 (ja) 2005-06-28 2011-03-23 パイオニア株式会社 放送受信装置、妨害検出装置および妨害検出方法
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
WO2011124509A1 (de) 2010-03-30 2011-10-13 Behr Gmbh & Co. Kg Temperierelement und temperiervorrichtung für ein fahrzeug
CN103261220B (zh) * 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
DK3725807T3 (da) * 2012-12-03 2026-01-12 Novimmune Sa Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016194992A1 (ja) 2015-06-05 2016-12-08 中外製薬株式会社 免疫活性化剤の併用
MX2018002043A (es) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
AU2016378573A1 (en) 2015-12-22 2018-07-19 Regeneron Pharmaceuticals, Inc. Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
US11072666B2 (en) * 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CN111201031B (zh) * 2017-08-25 2024-11-01 诺夫免疫股份有限公司 抗CD47 x抗间皮素抗体及其使用方法
JPWO2019244973A1 (ja) * 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
CN111454357B (zh) 2019-08-14 2022-03-15 康诺亚生物医药科技(成都)有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
CN114573702A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种新型肿瘤衔接器治疗药物的开发和应用
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技(成都)有限公司 一种t细胞衔接器治疗剂的开发和应用

Similar Documents

Publication Publication Date Title
JP2025016538A5 (https=)
JP2024109678A5 (https=)
JP2022191383A5 (https=)
JP2025111463A5 (https=)
JP2024534545A5 (https=)
JP2023526774A5 (https=)
JP2021507698A5 (https=)
JP2023506750A5 (https=)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2021533159A5 (https=)
JP2019501883A5 (https=)
JP2017537896A5 (https=)
JP2023516195A5 (https=)
JP2025501775A5 (https=)
JP2024520666A5 (https=)
JP2017534646A5 (https=)
JP2024024114A5 (https=)
JP2023093753A5 (https=)
JP2017534644A5 (https=)
JP2024537779A5 (https=)
JP2025067915A5 (https=)
JP2021534797A5 (https=)
JP2025038088A5 (https=)
JP2020522280A5 (https=)
JP2023548529A5 (https=)